A consortium led by Merus BV of the Netherlands is set to receive €5.9 million from the European Union’s FP7 programme to develop a prospective antibody-based therapy and screening tools for patients with metastatic colorectal cancer. ---Subscribe to MedNous to access this article--- Research & University News Company News
